A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency

201753 citationsJournal Articlehybrid Open Access

Authors

Pierre Chatelain · Université Claude Bernard Lyon 1

O. A. Malievskiy · Bashkir State Medical University

Klaudziya Radziuk · 9th City Clinical Hospital

Ганна Сергіївна Сенаторова · Kharkiv National Medical University

Magdy Abdou · Alexandria University

Elpis Vlachopapadopoulou · Panagiotis & Aglaia Kyriakou Children's Hospital

Yulia Skorodok

Abstract

The results suggest that long-acting TransCon GH is comparable to daily Genotropin for GH (pharmacokinetics) and IGF-1 (pharmacodynamics) levels, safety, and efficacy and support advancement into phase 3 development.

Topics & Keywords

Growth Hormone and Insulin-like Growth Factors Pituitary Gland Disorders and Treatments Adrenal Hormones and Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 102, Issue 5, pp. 1673-1682

DOI: 10.1210/jc.2016-3776

Field-Weighted Citation Impact: 2.48